Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy

Oncotarget

Volumn 7, Issue 36, 2016, Pages 58684-58695

  Park, Geon Tae ^a   Choi, Kyung Chul ^a,b  

^a Chungbuk National University   (South Korea)

^b TheraCell Bio and Science   (South Korea)

Author keywords

Cancer treatment; Metastatic cancer; Oncolytic virotherapy; Therapeutic stem cell

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CARBOXYLESTERASE; CD40 LIGAND; CHEMOKINE RECEPTOR CXCR4; CYTOSINE DEAMINASE; FIRTECAN; FLUCYTOSINE; INTERLEUKIN 12; IRINOTECAN; ONCOLYTIC VIRUS; PRODRUG; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS GLYCOPROTEIN; VIRUS GLYCOPROTEIN; ANTINEOPLASTIC AGENT;

5 FC GENE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CD GENE; CD40L GENE; CLINICAL TRIAL (TOPIC); DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG SPECIFICITY; GENE EXPRESSION; GENE TRANSFER; HUMAN; IFN GENE; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS; MOLECULARLY TARGETED THERAPY; NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; ONCOLYTIC VIROTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SUICIDE GENE THERAPY; TRAIL GENE; TROPISM; ANIMAL; CELL PROLIFERATION; CYTOLOGY; NEOPLASM; PROCEDURES; SECOND CANCER; STEM CELL; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TRENDS; VIRUS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; GENE TRANSFER TECHNIQUES; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; ONCOLYTIC VIROTHERAPY; PRODRUGS; STEM CELL TRANSPLANTATION; STEM CELLS; TISSUE ENGINEERING; VIRUSES;

EID: 84988329719     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.11017     Document Type: Review

References (79)

1. Gupta GP and Massague J. Cancer metastasis: building a framework. Cell. 2006; 127:679-695.
2. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev. 2000; 19:IXI, 193-383.
3. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T and Anderson DG. Treating metastatic cancer with nanotechnology. Nat Rev Cancer. 2012; 12:39-50.
4. Engel J, Lategahn J and Rauh D. Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer. ACS Med Chem Lett. 2016; 7:2-5.
5. Jacot W, Pons E, Frenel JS, Guiu S, Levy C, Heudel PE, Bachelot T, D'Hondt V, Darlix A, Firmin N, Romieu G, Thezenas S and Dalenc F. Efficacy and safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer with brain metastases. Breast Cancer Res Treat. 2016.
6. Shojaei S, Gardaneh M and Rahimi Shamabadi A. Target points in trastuzumab resistance. Int J Breast Cancer. 2012; 2012:761917.
7. Valabrega G, Montemurro F and Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007; 18:977-984.
8. McCubrey JA, Abrams SL, Fitzgerald TL, Cocco L, Martelli AM, Montalto G, Cervello M, Scalisi A, Candido S, Libra M and Steelman LS. Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis. Adv Biol Regul. 2015; 57:75-101.
9. Sosa MS, Bragado P and Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014; 14:611-622.
10. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
11. Klein CA. The systemic progression of human cancer: a focus on the individual disseminated cancer cell-the unit of selection. Adv Cancer Res. 2003; 89:35-67.
12. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3:453-458.
13. Zhang S, Liu XZ, Liu ZL, Shang CZ and Hu QL. Tropism mechanism of stem cells targeting injured brain tissues by stromal cell-derived factor-1. Chin J Traumatol. 2009; 12:263-268.
14. Koizumi S, Gu C, Amano S, Yamamoto S, Ihara H, Tokuyama T and Namba H. Migration of mouse-induced pluripotent stem cells to glioma-conditioned medium is mediated by tumor-associated specific growth factors. Oncol Lett. 2011; 2:283-288.
15. Park SA, Ryu CH, Kim SM, Lim JY, Park SI, Jeong CH, Jun JA, Oh JH, Park SH, Oh W and Jeun SS. CXCR4-transfected human umbilical cord blood-derived mesenchymal stem cells exhibit enhanced migratory capacity toward gliomas. Int J Oncol. 2011; 38:97-103.
16. Shi M, Li J, Liao L, Chen B, Li B, Chen L, Jia H and Zhao RC. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica. 2007; 92:897-904.
17. Gutova M, Najbauer J, Frank RT, Kendall SE, Gevorgyan A, Metz MZ, Guevorkian M, Edmiston M, Zhao D, Glackin CA, Kim SU and Aboody KS. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells. 2008; 26:1406-1413.
18. Schmidt NO, Przylecki W, Yang W, Ziu M, Teng Y, Kim SU, Black PM, Aboody KS and Carroll RS. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia. 2005; 7:623-629.
19. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, Ye L and Zhang X. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008; 18:500-507.
20. Schichor C, Albrecht V, Korte B, Buchner A, Riesenberg R, Mysliwietz J, Paron I, Motaln H, Turnsek TL, Jurchott K, Selbig J and Tonn JC. Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp Neurol. 2012; 234:208-219.
21. Stuckey DW and Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 2013; 19:685-694.
22. Posner MR, Cavacini LA, Upton MP, Tillman KC, Gornstein ER and Norris CM, Jr. Surface membraneexpressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines. Clin Cancer Res. 1999; 5:2261-2270.
23. Alexandroff AB, Jackson AM, Paterson T, Haley JL, Ross JA, Longo DL, Murphy WJ, James K and Taub DD. Role for CD40-CD40 ligand interactions in the immune response to solid tumours. Mol Immunol. 2000; 37:515-526.
24. Biagi E, Yvon E, Dotti G, Amrolia PJ, Takahashi S, Popat U, Marini F, Andreeff M, Brenner MK and Rousseau RF. Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. Hum Gene Ther. 2003; 14:545-559.
25. Loskog A and Totterman TH. CD40L-a multipotent molecule for tumor therapy. Endocr Metab Immune Disord Drug Targets. 2007; 7:23-28.
26. Ullenhag G and Loskog AS. AdCD40L-crossing the valley of death? Int Rev Immunol. 2012; 31:289-298.
27. Zhu D, Chen C, Purwanti YI, Du S, Lam DH, Wu C, Zeng J, Toh HC and Wang S. Induced pluripotent stem cell-derived neural stem cells transduced with baculovirus encoding CD40 ligand for immunogene therapy in mouse models of breast cancer. Hum Gene Ther. 2014; 25:747-758.
28. Purwanti YI, Chen C, Lam DH, Wu C, Zeng J, Fan W and Wang S. Antitumor effects of CD40 ligand-expressing endothelial progenitor cells derived from human induced pluripotent stem cells in a metastatic breast cancer model. Stem Cells Transl Med. 2014; 3:923-935.
29. Garrison JI, Berens ME, Shapiro JR, Treasurywala S and Floyd-Smith G. Interferon-beta inhibits proliferation and progression through S phase of the cell cycle in five glioma cell lines. J Neurooncol. 1996; 30:213-223.
30. Ren C, Kumar S, Chanda D, Chen J, Mountz JD and Ponnazhagan S. Therapeutic potential of mesenchymal stem cells producing interferon-alpha in a mouse melanoma lung metastasis model. Stem Cells. 2008; 26:2332-2338.
31. Ren C, Kumar S, Chanda D, Kallman L, Chen J, Mountz JD and Ponnazhagan S. Cancer gene therapy using mesenchymal stem cells expressing interferon-beta in a mouse prostate cancer lung metastasis model. Gene Ther. 2008; 15:1446-1453.
32. Jeong KY, Lee EJ, Kim SJ, Yang SH, Sung YC and Seong J. Irradiation-induced localization of IL-12-expressing mesenchymal stem cells to enhance the curative effect in murine metastatic hepatoma. Int J Cancer. 2015; 137:721-730.
33. Longley DB, Harkin DP and Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3:330-338.
34. Kline CL and El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel). 2013; 6:988-1038.
35. Yi BR, Kim SU and Choi KC. Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer. 2016;7:5985-99. doi: 10.18632/oncotarget.6719.
36. Zhao D, Najbauer J, Annala AJ, Garcia E, Metz MZ, Gutova M, Polewski MD, Gilchrist M, Glackin CA, Kim SU and Aboody KS. Human neural stem cell tropism to metastatic breast cancer. Stem Cells. 2012; 30:314-325.
37. Yi BR, Kim SU and Choi KC. Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice. Oncotarget. 2014; 5:12835-12848. doi: 10.18632/oncotarget.2547.
38. Stuckey DW and Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat Rev Cancer. 2014; 14:683-691.
39. Bateman A, Bullough F, Murphy S, Emiliusen L, Lavillette D, Cosset FL, Cattaneo R, Russell SJ and Vile RG. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 2000; 60:1492-1497.
40. Zhu D, Lam DH, Purwanti YI, Goh SL, Wu C, Zeng J, Fan W and Wang S. Systemic delivery of fusogenic membrane glycoprotein-expressing neural stem cells to selectively kill tumor cells. Mol Ther. 2013; 21:1621-1630.
41. Cattaneo R, Miest T, Shashkova EV and Barry MA. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol. 2008; 6:529-540.
42. Anderson BD, Nakamura T, Russell SJ and Peng KW. High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res. 2004; 64:4919-4926.
43. Yu Z, Chan MK, P Oc, Eisenberg DP, Shah JP, Singh B, Fong Y and Wong RJ. Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin Cancer Res. 2005; 11:4889-4897.
44. Guo P, Huang J, Wang L, Jia D, Yang J, Dillon DA, Zurakowski D, Mao H, Moses MA and Auguste DT. ICAM-1 as a molecular target for triple negative breast cancer. Proc Natl Acad Sci U S A. 2014; 111:14710-14715.
45. Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, Beagley L, Johansson ES, Hersey P and Barry RD. Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res. 2004; 10:53-60.
46. Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R and Malmberg KJ. Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells. J Immunol. 2009; 183:4921-4930.
47. Ulasov IV, Rivera AA, Han Y, Curiel DT, Zhu ZB and Lesniak MS. Targeting adenovirus to CD80 and CD86 receptors increases gene transfer efficiency to malignant glioma cells. J Neurosurg. 2007; 107:617-627.
48. Ulasov IV, Tyler MA, Zheng S, Han Y and Lesniak MS. CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum Gene Ther. 2006; 17:556-564.
49. Nandi S, Ulasov IV, Rolle CE, Han Y and Lesniak MS. A chimeric adenovirus with an Ad 3 fiber knob modification augments glioma virotherapy. J Gene Med. 2009; 11:1005-1011.
50. Guse K, Ranki T, Ala-Opas M, Bono P, Sarkioja M, Rajecki M, Kanerva A, Hakkarainen T and Hemminki A. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther. 2007; 6:2728-2736.
51. Morizono K, Xie Y, Ringpis GE, Johnson M, Nassanian H, Lee B, Wu L and Chen IS. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med. 2005; 11:346-352.
52. Lu B, Makhija SK, Nettelbeck DM, Rivera AA, Wang M, Komarova S, Zhou F, Yamamoto M, Haisma HJ, Alvarez RD, Curiel DT and Zhu ZB. Evaluation of tumor-specific promoter activities in melanoma. Gene Ther. 2005; 12:330-338.
53. Latham JP, Searle PF, Mautner V and James ND. Prostatespecific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. 2000; 60:334-341.
54. Zhu ZB, Makhija SK, Lu B, Wang M, Kaliberova L, Liu B, Rivera AA, Nettelbeck DM, Mahasreshti PJ, Leath CA, 3rd, Yamamoto M, Alvarez RD and Curiel DT. Transcriptional targeting of adenoviral vector through the CXCR4 tumorspecific promoter. Gene Ther. 2004; 11:645-648.
55. Cawood R, Wong SL, Di Y, Baban DF and Seymour LW. MicroRNA controlled adenovirus mediates anti-cancer efficacy without affecting endogenous microRNA activity. PLoS One. 2011; 6:e16152.
56. Mayr C, Hemann MT and Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science. 2007; 315:1576-1579.
57. Edge RE, Falls TJ, Brown CW, Lichty BD, Atkins H and Bell JC. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther. 2008; 16:1437-1443.
58. Suzuki T, Sakurai F, Nakamura S, Kouyama E, Kawabata K, Kondoh M, Yagi K and Mizuguchi H. miR-122a-regulated expression of a suicide gene prevents hepatotoxicity without altering antitumor effects in suicide gene therapy. Mol Ther. 2008; 16:1719-1726.
59. Tong AW, Senzer N, Cerullo V, Templeton NS, Hemminki A and Nemunaitis J. Oncolytic viruses for induction of antitumor immunity. Curr Pharm Biotechnol. 2012; 13:1750-1760.
60. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R and Nemunaitis JJ. Phase II clinical trial of a granulocytemacrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009; 27:5763-5771.
61. Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA and Restifo NP. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol Ther. 2013; 21:1369-1377.
62. Poutou J, Bunuales M, Gonzalez-Aparicio M, Garcia-Aragoncillo E, Quetglas JI, Casado R, Bravo-Perez C, Alzuguren P and Hernandez-Alcoceba R. Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model. Gene Ther. 2015; 22:696-706.
63. Odintsova E, Sugiura T and Berditchevski F. Attenuation of EGF receptor signaling by a metastasis suppressor, the tetraspanin CD82/KAI-1. Curr Biol. 2000; 10:1009-1012.
64. Takeda T, Hattori N, Tokuhara T, Nishimura Y, Yokoyama M and Miyake M. Adenoviral transduction of MRP-1/ CD9 and KAI1/CD82 inhibits lymph node metastasis in orthotopic lung cancer model. Cancer Res. 2007; 67:1744-1749.
65. Mandai M, Konishi I, Koshiyama M, Mori T, Arao S, Tashiro H, Okamura H, Nomura H, Hiai H and Fukumoto M. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 1994; 54:1825-1830.
66. Muller W, Schneiders A, Hommel G and Gabbert HE. Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis. Cancer. 1998; 83:2481-2487.
67. Sirotkovic-Skerlev M, Krizanac S, Kapitanovic S, Husnjak K, Unusic J and Pavelic K. Expression of c-myc, erbB-2, p53 and nm23-H1 gene product in benign and malignant breast lesions: coexpression and correlation with clinicopathologic parameters. Exp Mol Pathol. 2005; 79:42-50.
68. Li J, Zhou J, Chen G, Wang H, Wang S, Xing H, Gao Q, Lu Y, He Y and Ma D. Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther. 2006; 13:266-272.
69. Akhtari M, Mansuri J, Newman KA, Guise TM and Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther. 2008; 7:3-9.
70. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL and Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A. 2005; 102:13909-13914.
71. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, et al. Molecular definition of breast tumor heterogeneity. Cancer Cell. 2007; 11:259-273.
72. Zhang Z, Hu Z, Gupta J, Krimmel JD, Gerseny HM, Berg AF, Robbins JS, Du H, Prabhakar B and Seth P. Intravenous administration of adenoviruses targeting transforming growth factor beta signaling inhibits established bone metastases in 4T1 mouse mammary tumor model in an immunocompetent syngeneic host. Cancer Gene Ther. 2012; 19:630-636.
73. Cody JJ, Rivera AA, Lyons GR, Yang SW, Wang M, Sarver DB, Wang D, Selander KS, Kuo HC, Meleth S, Feng X, Siegal GP and Douglas JT. Arming a replicating adenovirus with osteoprotegerin reduces the tumor burden in a murine model of osteolytic bone metastases of breast cancer. Cancer Gene Ther. 2010; 17:893-905.
74. Castellano D, Sepulveda JM, Garcia-Escobar I, Rodriguez-Antolin A, Sundlov A and Cortes-Funes H. The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist. 2011; 16:136-145.
75. Koch L. Cancer: RANKL inhibition-a new weapon against breast cancer? Nat Rev Endocrinol. 2011; 7:2.
76. Kim J, Hall RR, Lesniak MS and Ahmed AU. Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions. Viruses. 2015; 7:6200-6217.
77. Stoff-Khalili MA, Rivera AA, Mathis JM, Banerjee NS, Moon AS, Hess A, Rocconi RP, Numnum TM, Everts M, Chow LT, Douglas JT, Siegal GP, Zhu ZB, Bender HG, Dall P, Stoff A, et al. Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat. 2007; 105:157-167.
78. Mader EK, Butler G, Dowdy SC, Mariani A, Knutson KL, Federspiel MJ, Russell SJ, Galanis E, Dietz AB and Peng KW. Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med. 2013; 11:20.
79. Ong HT, Federspiel MJ, Guo CM, Ooi LL, Russell SJ, Peng KW and Hui KM. Systemically delivered measles virusinfected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol. 2013; 59:999-1006.